Fact CheckerSign in

NCT06929221Not yet recruiting

The Effect of Bedside Whiteboard Use on Anxiety, Depression and Nursing Care in Chronic Obstructive Pulmonary Patients

Source: ClinicalTrials.gov · Last updated 1 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

ABSTRACT Chronic obstructive pulmonary disease (COPD) is a disease characterized by the inability of the body to adequately exchange gases, resulting in progressive shortness of breath that can form secretions and compromise the performance of daily activities. COPD is reported as the third most common cause of death worldwide, with 3.23 million deaths in 2019. Anxiety and depression are common in individuals with COPD. However, COPD is more common in patients with other chronic diseases such as hypertension, diabetes, cancer or musculoskeletal disorders. Communication is a key component in interprofessional care as well as in improving patient care outcomes. Strategies to address gaps in the quality of information and communication between patients, caregivers and professionals improve patient safety as well as quality of care. One of these strategies is the use of whiteboards at the bedside. The use of whiteboards at the bedside has emerged as a strategy to improve interprofessional team participation, communication and information sharing with care teams, patients and families. This study will be conducted in randomized controlled single blind parallel groups to examine the effect of bedside whiteboard use on anxiety, depression and nursing care satisfaction in COPD patients. The research will consist of patients who are hospitalized in Atatürk University Research Hospital Chest Diseases Clinic and who meet the inclusion criteria. In the results of the research, it is thought that the use of whiteboard will affect the communication between health care team members.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
128 (estimated)
First submitted
22 Mar 2025
Start date
15 Dec 2025
Primary completion date
15 Apr 2026
Lead sponsor
Agri Ibrahim Cecen University
Diseases
COPD
NCT number
NCT06929221

What you commit to

  • Study type: Interventional
  • Planned participants: 128
  • From 15 Dec 2025 to the primary completion date, 15 Apr 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • \- Having strong reading and comprehension skills

Who the study is looking for

  • 18 years of age or older
  • Having a medical diagnosis of COPD
  • To be in a condition to be followed up with at least 7 days

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.